Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 10

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 10
---
 entire Prospectus carefully, including the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes thereto, in each case included in this Prospectus. Some of the statements in this Prospectus constitute forward-looking statements. See “Special Note About Forward-Looking Statements.” Except as otherwise indicated, referenced to the “Company,” “we,” “us” and “our” refer to Revium Rx., a Delaware corporation, prior to the reincorporation from Delaware to Nevada, and Revium, Rx., a Nevada corporation, following that reincorporation, and our wholly-owned subsidiaries, Revium RX Ltd.(formerly known as Revium Recovery Ltd.) and LipoVation Ltd. (“LipoVation”), which became our wholly-owned subsidiary on July 23, 2024.

Revium Rx is
a preclinical biotechnology company developing next-generation, lipid-based therapies to address some of the most pressing challenges
in medicine. We focus on creating smarter, more targeted treatments that improve how medicines work in the body, with the goal of increasing
effectiveness while reducing side effects. We are developing advanced lipid-based platforms for a variety of potential uses, including
areas with high unmet-needs such as antimicrobial resistance and solid tumors. Our planned clinical trials aim to expand the therapeutic
horizons of hard-to-treat diseases by amplifying, improving, and unleashing the potential of encapsulated therapeutics to enhance delivery
and achieve a controlled release. This includes antimicrobial resistance and solid tumors being as they are areas with high unmet need.

We use tiny, specially designed fat-based
particles called liposomes to carry powerful medicines directly to where they’re needed in the body. This method is one of the
most advanced ways to deliver medicine and allows the drugs to stay in the bloodstream longer, reach their target more precisely, and
release their effects in a controlled way. This approach leads to treatments that are more effective and have a reduced risk of side
effects. We are leveraging these features to concentrate our treatments in diseased tissues, such as tumors and infected areas, while
avoiding healthy cells. We are committed to addressing unmet medical needs in antibiotic resistant microbial, oncology, and immunology
through the development of lipid-based therapeutics. By combining established pharmacology with advanced lipid delivery systems, we aim
to improve drug efficacy, optimize safety profiles, and enable targeted delivery—advancing treatment options where existing therapies
are limited.